Selank+Semax Blend Protocol
Combination of two Russian-origin peptides studied for anxiolytic and nootropic effects.
- Cycle
- 4–8 weeks
Evidence Level: Investigational / Theoretical
Primarily preclinical or very limited human data — mechanism-based reasoning more than a demonstrated clinical effect. Treat as investigational.
Human evidence: No combination-specific human trials — see individual Selank and Semax entries.
Animal evidence: No combination-specific animal trials.
Introduction & Mechanism of Action
Combination of two Russian-origin peptides studied for anxiolytic and nootropic effects.
Pairs Selank's tuftsin-analog anxiolytic/immune-modulating mechanism with Semax's ACTH-fragment BDNF-linked cognitive mechanism — two distinct CNS-active research angles in one product.
Receptors/targets: See individual Selank and Semax entries
Areas of Research Interest
- Anxiolytic research
- Cognitive-performance studies
Benefits Reported in Research
- Anxiolytic research
- Cognitive-performance studies
Reported Research Dosing Range
The figures below are cited from published research literature and protocol references — they describe what has been studied, not a personal prescription or instruction.
Reported range: 250–500 mcg per component
Reported frequency: 1× daily, intranasal
Reported cycle duration: 4–8 weeks
Escalation & maintenance: A dedicated weekly escalation and maintenance schedule specific to this peptide has not yet been published here — follow the dose range and frequency above, titrating conservatively from the low end, and consult a physician before adjusting.
Side Effects
- Nasal irritation
Contraindications
- Pregnancy
- Seizure disorder (theoretical concern)
Drug interactions
- Not characterized for the combination
Safety
- Combines the individually limited safety profiles of both components
Combination-specific human data is essentially absent; evidence for each peptide individually does not establish combined-product safety or effect.
Expected Results & Comparison
Combination-specific human data is essentially absent; evidence for each peptide individually does not establish combined-product safety or effect. Choose based on which single mechanism (anxiolytic vs. cognitive) is the actual research interest if combination evidence matters to you.